Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

GeoVax Labs (GOVX) EBITDA (2016 - 2025)

GeoVax Labs' EBITDA history spans 16 years, with the latest figure at -$4.4 million for Q4 2025.

  • Quarterly results put EBITDA at -$4.4 million for Q4 2025, up 46.77% from a year ago — trailing twelve months through Dec 2025 was -$21.6 million (up 13.94% YoY), and the annual figure for FY2025 was -$21.6 million, up 13.94%.
  • EBITDA for Q4 2025 was -$4.4 million at GeoVax Labs, up from -$6.4 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$1.5 million in Q2 2021 to a low of -$13.7 million in Q4 2021.
  • The 5-year median for EBITDA is -$5.4 million (2022), against an average of -$5.3 million.
  • The sharpest move saw EBITDA tumbled 927.89% in 2021, then skyrocketed 60.8% in 2022.
  • Year by year, EBITDA stood at -$13.7 million in 2021, then skyrocketed by 60.8% to -$5.4 million in 2022, then tumbled by 42.81% to -$7.7 million in 2023, then decreased by 8.46% to -$8.3 million in 2024, then soared by 46.77% to -$4.4 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$4.4 million, -$6.4 million, and -$5.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.